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Purpose: To determine whether chronic obstructive pulmonary disease (COPD) is a risk 
factor for hip fracture and identify other factors associated with hip fracture.
Patients and Methods: Observational nested case–control study was conducted in Aragon, 
Spain in 2010. We included COPD patients aged >40 years, in the EpiChron cohort. Each COPD 
patient was matched for age, sex, and number of comorbidities with a control subject without 
COPD. Patients with an existing diagnosis of osteoporosis and those with hip fracture before 
2011 were excluded. We collected baseline demographic, comorbidity, and pharmacological 
treatment data. During a 5-year follow-up period, we recorded the incidence of hip fracture. 
A logistic regression model was constructed to identify factors associated with hip fracture.
Results: The study population consisted of 26,517 COPD patients and the same number of 
controls (median [interquartile range] age, 74 [17] years; women, 24.7%). Smoking and heart 
failure were more frequent in COPD patients, and obesity, hypertension, diabetes, dyslipi-
demia, stroke, arthritis, and visual or hearing impairment were less frequent (all p<0.001). 
Consumption of benzodiazepines (p=0.037), bronchodilators (p<0.001), and corticosteroids 
(p<0.001) was higher in the COPD group, while that of beta-blockers and thiazides was 
lower (both p<0.001). During follow-up, 898 (1.7%) patients experienced hip fracture, with 
no differences observed between COPD and control patients. Multivariate analysis revealed 
that independent of COPD status, age, female sex, chronic liver disease, heart failure, and 
benzodiazepine use were independently associated with a higher risk of hip fracture, and 
obesity with a lower risk. In COPD patients, use of inhaled anticholinergics was indepen-
dently associated with hip fracture (OR, 1.390; 95% CI 1.134–1.702; p=0.001).
Conclusion: COPD is not a risk factor for a hip fracture within 5 years. The association 
between the use of inhaled anticholinergics and risk of hip fracture warrants further study.
Keywords: chronic obstructive pulmonary disease, hip fracture, case–control study, 
incidence
Introduction
The world population is aging. Recent years have seen an increase in life expectancy 
in Spain and in the rest of the world. According to the World Health Organization, 
between 2015 and 2050 the proportion of the population aged 60 years and over will 
increase from 12% to 22% worldwide, an increase of 1.1 billion.1
Hip fracture is an age-associated health problem that frequently causes disability 
and worsening quality of life, leading to high healthcare costs and high mortality.2 
Frailty and osteoporosis are known causes of hip fracture.3
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Chronic obstructive pulmonary disease (COPD) consti-
tutes a public health problem owing to its high prevalence, 
morbidity, and mortality. The World Health Organization 
estimates that by 2030 COPD will become the third cause of 
death globally.4 In addition to affecting the airways, COPD 
also has extrapulmonary effects. Malnutrition, falls, and 
osteoporosis, all of which are also associated with hip 
fracture, are more frequent in COPD patients.5–7
Some studies have reported a decrease in bone mass in 
COPD patients.8 Using the FRAX tool, a study of COPD 
patients hospitalized for exacerbation found that half of all 
patients were at high risk of hip fracture within 10 years.9
The objective of this study was to determine the inci-
dence of hip fracture in COPD patients and to identify 
possible factors related to its occurrence.
Patients and Methods
Design
We conducted an observational nested case–control study 
in the EpiChron cohort in 2010. The cohort, which has 
been previously described,10 consisted of anonymous 
demographic, clinical, and drug dispensing data from all 
users of the public health system of Aragon, Spain. The 
Spanish national health system provides free healthcare 
with universal coverage to approximately 95% of the 
population in Aragon.
Participants
We included the individuals >40 years old in the EpiChron 
cohort with a diagnosis of COPD recorded in their primary 
healthcare and/or hospital electronic records. Patients with 
a previous diagnosis of osteoporosis and those who had 
experienced hip fracture before 2010 were excluded. For 
each case, we selected a COPD-free control matched for 
age, sex, and number of comorbidities.
For each patient, the following variables were collected: 
age, sex, smoking status, alcohol consumption, diagnosed 
chronic diseases, and prescribed drugs. Disease diagnoses 
recorded in primary care and hospital electronic health 
records were coded according to the International 
Classification of Primary Care (ICPC) and the International 
Classification of Diseases, 9th Revision (ICD-9), respec-
tively. Prescribed drugs were classified according to the 
third level of the Anatomical Therapeutic Chemical (ATC) 
Classification System (ie, by pharmacological subgroup).
Participants were followed for 5 years (until 
December 31, 2015), or until death or removal from the 
database of health system users. The incidence of hip 
fracture, as defined by ICD-9 codes 820.0–820.9,11 was 
recorded during the follow-up period.
The study was approved by the Clinical Research 
Ethics Committee of Aragón (PI 18/131) and carried out 
in accordance with the principles of the Declaration of 
Helsinki and Spain’s Organic Law for the Protection of 
Personal Data. The ethics committee waived the require-
ment for informed consent given the epidemiological nat-
ure of the project, which used anonymized data and did 
not involve any type of intervention.
Statistical Analysis
We described the baseline demographic and clinical char-
acteristics of the study population based on the presence or 
absence of COPD. Qualitative variables were expressed as 
frequencies or percentages and quantitative variables as 
the median and interquartile range. Qualitative variables 
were compared using the Chi-squared test and quantitative 
variables using the Mann Whitney U-test.
To study the factors associated with the incidence of 
hip fracture, we performed a logistic regression model 
with the enter method, using in the multivariate model 
those variables associated with p-value <0.1 in the uni-
variate model. We constructed Kaplan–Meier curves to 
analyze the incidence of hip fracture and compared them 
using the Log rank test.
In every case, we established the level of statistical sig-
nificance for a value of p<0.05. We used the Statistical 
Package for the Social Sciences (SPSS; version 21.0 for 
Windows) for all statistical analyses.
Results
Figure 1 shows the flowchart of included patients. In 
December 2010, the EpiChron cohort consisted of 
1,314,450 subjects and 577,934 had no exclusion criteria. 
Of them, 26,517 had a diagnosis of COPD.
Patient Characteristics
The baseline characteristics of subjects with and without 
COPD are presented in Table 1. The median [interquartile 
range] age was 74 [17] years, and 24.7% of the study popula-
tion were women. The prevalence of smoking and heart failure 
was higher in the COPD group (20.4% vs 11.8%, p<0.001, 
and 18.3% vs 13.0%, p<0.001, respectively), while that of 
obesity (18.3% vs 21.1%), high blood pressure (61.4% vs 
70.4%), diabetes (27.0% vs 33.9%), dyslipidemia (43.8% vs 
54.2%), stroke (14.5% vs 18.0%), arthritis (25.8% vs 32.8%), 
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and visual (8.6% vs 10.0%) or hearing impairment (13.0% vs 
15.5%) was lower (all p<0.001). Consumption of benzodiaze-
pines (23.2% vs 22.4%; p=0.037), bronchodilators, and corti-
costeroids (both p<0.001) was higher in the COPD group, 
while that of beta-blockers and thiazides was lower (both 
p<0.001).
Incidence of Hip Fracture
During the 5-year follow-up period, 898 (1.7%) patients 
experienced hip fracture, with no evident differences in 
incidence between the COPD and the control group 
(Figure 2). Table 2 shows the differences between patients 
with and without hip fracture in COPD and control groups. 
There was no association between COPD and hip fracture 
(OR 1.042, 95% CI 0.913–1.189) even when we adjusted 
the model for age, sex, systemic corticosteroids, obesity, 
hypertension, hyperlipidemia, arthritis, heart failure, 
stroke, chronic liver disease, smoking, alcoholism, use of 
benzodiazepines, inhaled anticholinergics agents and cal-
cium (OR 0.975, 95% CI 0.843–1.128). Multivariate ana-
lysis revealed that independent of COPD status, age, 
female sex, chronic liver disease, heart failure, and benzo-
diazepine use were independently associated with a higher 
risk of hip fracture, and obesity with a lower risk. 
Hyperlipidemia and stroke were associated with hip frac-
ture in patients without COPD. The use of inhaled antic-
holinergics was independently associated with hip fracture 
in COPD patients (OR, 1.390; 95% CI 1.134–1.702; 
p = 0.001) (Table 3).
Discussion
COPD is a poor prognostic factor in patients with hip 
fracture. Studies using databases in Japan, Denmark, the 
United Kingdom, and the United States have found that 
COPD is associated with higher mortality in the short and 
medium term in patients with hip fracture.12–16 Moreover, 
COPD patients more frequently develop surgical wound 
Figure 1 Flowchart of patients included in the study.
Table 1 Baseline Characteristics of the Study Population with 








Demographic and lifestyle 
(n, %)
Women 6551 (24.7) 6551 (24.7) 1.000
Age (Median, IQR) 74 (17) 74 (17) 1.000
Body mass index (Median, 
IQR)
29.0 (6.4) 29.2 (5.8) <0.001
Active smoking 5399 (20.4) 3131 (11.8) <0.001
Alcoholism 5883 (22.2) 6026 (22.7) 0.139
Comorbidities (n, %)
Number (Median, IQR) 4 (5) 5 (5) <0.001
Obesity 4854 (18.3) 5577 (21.1) <0.001
Hypertension 16,264 (61.4) 18,648 (70.4) <0.001
Diabetes 7161 (27.0) 8972 (33.9) <0.001
Hyperlipidemia 11,603 (43.8) 14,358 (54.2) <0.001
Chronic liver disease 579 (2.2) 555 (2.1) 0.488
Heart failure 4849 (18.3) 3432 (13.0) <0.001
Stroke 3831 (14.5) 4763 (18.0) <0.001
Arthritis 6823 (25.8) 8676 (32.8) <0.001
Visual impairment 2278 (8.6) 2645 (10.0) <0.001
Hearing impairment 3437 (13.0) 4100 (15.5) <0.001
Prescribed drugs (n, %)
Benzodiazepines 6151 (23.2) 5948 (22.4) 0.037
Systemic corticosteroids 2044 (7.7) 1075 (4.1) <0.001
Inhaled beta adrenergics, 
plain
3676 (13.9) 450 (1.7) <0.001
Inhaled beta adrenergics, 
double therapy
7363 (27.8) 991 (3.7) <0.001
Inhaled glucocorticoids 972 (3.7) 143 (0.5) <0.001
Inhaled anticholinergics 7589 (28.6) 788 (3.0) <0.001
Inhaled antiallergic agents 1 (0.0) 0 (0.0) 1.000
Systemic adrenergics, plain 22 (0.1) 8 (0.0) 0.018
Beta-blockers 2927 (11.0) 4744 (17.9) <0.001
Thiazides 234 (0.9) 316 (1.2) <0.001
Nonsteroidal anti- 
inflammatory drugs
3254 (12.3) 3351 (12.6) 0.207
Androgens 15 (0.1) 31 (0.1) 0.027
Estrogens 6 (0.0) 14 (0.1) 0.117
Calcium 637 (2.4) 632 (2.4) 0.910
Vitamin D 301 (1.1) 321 (1.2) 0.443
Bisphosphonates 288 (1.1) 250 (0.9) 0.109
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infections, respiratory infections, and sepsis, have longer 
hospital stays and require more time for rehabilitation.15–17
Osteoporosis is an important comorbidity of COPD. It 
is frequently undiagnosed and is associated with poorer 
health and a poor prognosis.18,19 Patients with both COPD 
and osteoporosis have more exacerbations and more 
hospitalizations.20 Furthermore, a higher rate of COPD 
exacerbations has been associated with an increased risk 
of osteoporosis and a greater decrease in bone mass.21,22 
A cross-sectional study conducted in Spain measured the 
risk of hip fracture within the following ten years using the 
FRAX tool, and observed that half of all patients hospita-
lized for COPD had a high risk (>3%).9 In a UK study, 
40% of COPD patients in primary care were deemed high- 
risk based on FRAX score, and 45.6% based on the 
QFracture score.23 Another UK study using the FRAX 
tool reported a high risk of hip fracture in outpatients 
with severe COPD.24 In line with these findings, a recent 
study identified COPD as a risk factor for hip fracture.25
A retrospective observational study by Miguel et al 
selected patients hospitalized for hip fracture using the 
Spanish Minimum Basic Data Set and found that the 
incidence of hip fracture was higher in patients with 
COPD.26 However, in this study, the incidence rates were 
calculated indirectly extrapolating data from other studies. 
Another Spanish population cohort study reported that of 
the comorbidities included in the Charlson index, COPD 
was associated with the occurrence of hip fracture in men 
with a relative risk of 1.20 (95% CI 1.03–1.40).27 
A retrospective case–control study of Taiwanese COPD 
patients found that the hazard ratio for hip fracture within 
two years was 1.57.28 In the Norwegian Hordaland Health 
Study, in which the general population was followed for 
ten years, COPD was associated with a higher incidence of 
hip fracture,8 and a greater degree of airway obstruction 
was associated with increased risk of hip fracture.
In contrast to previous studies, we did not observe an 
excess risk of hip fracture among COPD patients. Using 
an approach similar to ours, Akyea et al analyzed elec-
tronic health records and observed an increased risk of 
hip fracture among COPD patients, although this 
increase was not observed after adjusting for age, sex, 
Charlson index, body mass index, and the use of inhaled 
corticosteroids.23 In our study, we matched patients by 
age, sex, and number of comorbidities. In the Hordaland 
Health Study, patients with COPD were significantly 
Figure 2 Kaplan–Meier curves of incidence of hip fracture.
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older than those without, which may explain the higher 
incidence of hip fracture in this group.8 In the study by 
de Miguel et al, although the age of the study groups 
was similar, comorbidity was greater among COPD 
patients.26 Huang et al reported a higher risk of hip 
fracture among patients with COPD than those without, 
even after adjusting for age, sex, and comorbidities.28 
Furthermore, those authors used a follow-up period of 4 
years; 1 year less than that used in the present study. 
Based on the present findings and those reported to date, 
the relationship between COPD and hip fracture there-
fore remains unclear.
Several factors may explain the higher incidence of hip 
fractures among COPD patients. On the one hand, patients 
with poorer lung function tend to show a greater decrease in 
bone mass,29 and on the other hand, patients with COPD 
experience more falls than those without.7 Finally, patients 
with frequent COPD exacerbations are intermittently treated 
with high doses of systemic corticosteroids that can contribute 
to the appearance of fractures.30
Table 2 Characteristics of COPD Patients and Controls with and without Hip Fracture










Demographic and lifestyle (n, %)
Women 183 (40.0) 6368 (24.4) <0.001 165 (37.5) 6386 (24.5) <0.001
Age (Median, IQR) 83 (10) 74 (17) <0.001 83 (10) 74 (17) <0.001
Body mass index (Median, IQR) 27.5 (5.7) 29.0 (6.4) <0.001 27.2 (5.7) 29.2 (5.8) <0.001
Active smoking 42 (9.2) 5357 (20.6) <0.001 18 (4.1) 3113 (11.9) <0.001
Alcoholism 47 (10.3) 5836 (22.4) <0.001 49 (11.1) 5977 (22.9) <0.001
Comorbidities (n, %)
Number (Median, IQR) 5 (5) 4 (5) <0.001 7 (5) 5 (5) <0.001
Obesity 59 (12.9) 4795 (18.4) 0.003 51 (11.6) 5526 (21.2) <0.001
Hypertension 350 (76.4) 15,914 (61.1) <0.001 358 (81.4) 18,290 (70.2) <0.001
Diabetes 138 (30.1) 7023 (27.0) 0.147 170 (38.6) 8802 (33.8) 0.038
Hyperlipidemia 163 (35.6) 11,440 (44.0) <0.001 184 (41.8) 14,174 (54.4) <0.001
Chronic liver disease 17 (3.7) 562 (2.2) 0.037 17 (3.9) 538 (2.1) 0.015
Heart failure 169 (36.9) 4680 (18.0) <0.001 121 (27.5) 3311 (12.7) <0.001
Stroke 108 (23.6) 3723 (14.3) <0.001 157 (35.7) 4606 (17.7) <0.001
Arthritis 145 (31.7) 6678 (25.7) 0.004 167 (38.0) 8509 (32.7) 0.022
Visual impairment 46 (10.0) 2232 (8.6) 0.305 39 (8.9) 2606 (10.0) 0.477
Hearing impairment 73 (15.9) 3364 (12.9) 0.067 70 (15.9) 4030 (15.5) 0.853
Prescribed drugs (n, %)
Benzodiazepines 151 (33.0) 6000 (23.0) <0.001 132 (30.0) 5816 (22.3) <0.001
Systemic corticosteroids 40 (8.7) 2004 (7.7) 0.458 15 (3.4) 1060 (4.1) 0.569
Inhaled beta adrenergics, plain 65 (14.2) 3611 (13.9) 0.891 9 (2.0) 441 (1.7) 0.701
Inhaled beta adrenergics, double therapy 132 (28.8) 7231 (27.7) 0.649 20 (4.5) 971 (3.7) 0.439
Inhaled glucocorticoids 20 (4.4) 952 (3.7) 0.496 2 (0.5) 141 (0.5) 1.000
Inhaled anticholinergics 156 (34.1) 7433 (28.1) 0.011 13 (3.0) 775 (3.0) 1.000
Inhaled antiallergic agents 0 (0.0) 1 (0.0) 1.000 0 (0.0) 0 (0.0) 1.000
Systemic adrenergics, plain 0 (0.0) 22 (0.1) 1.000 1 (0.2) 7 (0.0) 0.125
Beta-blockers 44 (9.6) 2883 (11.1) 0.362 86 (19.5) 4658 (17.9) 0.395
Thiazides 5 (1.1) 229 (0.9) 0.817 2 (0.5) 314 (1.2) 0.224
Nonsteroidal anti-inflammatory drugs 61 (13.3) 3193 (12.3) 0.537 52 (11.8) 3299 (12.7) 0.653
Androgens 0 (0.0) 15 (0.1) 1.000 0 (0.0) 31 (0.1) 1.000
Estrogens 0 (0.0) 6 (0.0) 1.000 0 (0.0) 14 (0.1) 1.000
Calcium 20 (4.4) 617 (2.4) 0.009 14 (3.2) 618 (2.4) 0.342
Vitamin D 3 (0.7) 298 (1.1) 0.450 4 (0.9) 317 (1.2) 0.716
Bisphosphonates 8 (1.7) 280 (1.1) 0.251 10 (2.3) 240 (0.9) 0.009
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One surprising finding in our study was the association 
between hip fracture and treatment with anticholinergic 
bronchodilators in COPD patients. As early as 2011, Morden 
et al, in their analysis of data from the Veterans Administration 
database, reported that the use of inhaled corticosteroids was 
associated with hip and wrist fractures in men aged over 50 
years who were newly diagnosed with COPD.31 More recent 
studies reported only a modest increase in the risk of fracture, 
and only in patients receiving high doses of inhaled 
corticosteroids.32,33 Inhaled beta-agonists, especially when 
administered at high doses, have also been associated with 
femur fractures in COPD patients.34,35 To our knowledge, ours 
is the first study to report an association between antimuscari-
nics and the incidence of hip fracture. Given the frequency of 
osteoporosis and fractures in COPD patients, all pharmacov-
igilance studies with new bronchodilators should include frac-
tures as an adverse effect to be monitored.
The findings of this study are strengthened by the use 
of a population database that includes a large number of 
comorbidities and medications. Nonetheless, several study 
limitations should be noted. First, we excluded patients 
with previously diagnosed osteoporosis and those that had 
previously experienced hip fracture. It is possible that 
COPD causes greater exacerbation of pre-existing osteo-
porosis in these particular patients, increasing the likeli-
hood of new fractures, and that these patients were not 
accounted for in our analysis. Second, while studies using 
the FRAX tool have established that COPD patients are at 
high risk of hip fracture within ten years, the follow-up 
period in the present study was only five years. It is 
possible that hip fractures occur more frequently between 
five and ten years, and that our follow-up period was not 
sufficiently long to detect such fractures. In fact, the mean 
age of patients with hip fracture in Spain is 86.7 years, 
twelve years higher than in our patients.36
In conclusion, in our study population, COPD was not 
a risk factor for hip fracture within the next five years. 
However, studies with a longer follow-up period will be 
necessary to clarify any potential association. The possible 
association between treatment with inhaled anticholiner-
gics and hip fracture should be monitored and further 
researched in patients with COPD.
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